This week on H-SPAN, we sat down with Brian Cole, a state representative from New Hampshire who has recently announced his candidacy for the U.S. House of Representatives.
In this episode, we discuss Brian’s introduction to politics, what the government can do to advance aging research, and how New Hampshire is poised to emerge as the next state to embrace longevity science.
The Alliance for Longevity Initiatives (A4LI) is a 501(c)(4) nonprofit organization whose mission is to advance legislation and policies that aim to increase healthy human lifespan, with a focus on accelerating equitable access to next-generation therapies.
An internationally known expert on nutritional influences that affect trajectories of health and disability in older adults, including vitamins, protein, energy balance, exercise and obesity, I have more than 450 peer-reviewed publications, lead Wake Forest Baptist’s NIA-funded Claude D Pepper Older Americans Independence Center (OAIC), and co-direct the Sticht Center for Healthy Aging and Alzheimer’s Prevention. I have participated in some of the most important aging-related multicenter studies in the past 20 years, including the Health ABC study and the Life Style Interventions and Independence for Elders (LIFE) Trial, and I am the past editor-in-chief of the Journals of Gerontology: Medical Sciences.
I lead the Research Centers Collaborative Network (RCCN) with the American Federation for Aging Research. The RCCN’s goal is to build research collaborations among the six NIA Center’s programs through workshops, pilot awards, and educational activities. Through my service on the National Advisory Council on Aging, I help shape national research priorities for aging research. My recent work focuses on translating the new discoveries in the biology aging to prevent age-related diseases and extend health span in older adults.
Dr. Susanna Rosi is a Principal Investigator at the Altos Labs Bay Area Institute of Science.
Susanna is a Principal Investigator at the Altos Labs Bay Area Institute of Science. Prior to joining Altos, Susanna was the Lewis and Ruth Cozen Chair II, Professor in the Departments of Physical Therapy Rehabilitation Science and Neurological Surgery at UCSF. Susanna studies the mechanisms responsible for the cognitive dysfunctions observed after traumatic brain injury, therapeutic brain irradiation and galactic cosmic ray exposure. Her work provided the mechanistic evidence for the role of microglia in the development of cognitive deficits after brain injury based on sex. She was the first to demonstrate that modulation of the Integrated Stress Response rescues cognitive deficits after brain trauma; rejuvenates old mice by alleviating memory deficits and restoring neuronal and immune dysfunction. Susanna has been the recipient of several NCI, NIA, NINDS awards and she is a NASA investigator. Most recently she received the 2021 J.W. Osborne Award.
Tim Peterson, Ph.D. is CEO and Founder of BIOIO and of Healthspan Technologies. He is also a Core Member of the Longevity Working Group at VitaDAO.
BIOIO was founded by Tim in 2017 with the goal to better understand how drugs work. In particular, they leverage their learnings on how widely used medicines, such as rapamycin, metformin, bisphosphonates, and antidepressants, work. This led them to define a gold standard for drug Mechanism of Action (MoA) elucidation, leading to their genetics-based MOAT platform.
Petr Sramek is Managing Partner of Longevitytech.fund and co-founder of LongevityForum.eu. He is a serial entrepreneur in deep tech for more than 30 years. Petr is building science, funding and business infrastructure to support faster adoption of health-span improving technologies. Petr was Entrepreneur in Residence at Singularity University, co-founder of the Platform on Artificial Intelligence at the Confederation of Industry, AI Startup Incubator founder and a Senator for the Czech Republic in the World Business Angels Investment Forum (WBAF). Petr is also the founder of the AI Awards project. Petr has been featured in the group of 28 AI leaders in the flagship World Intellectual Property Organization study.
Dr. Xiaoxi (Sofie) Wei is an award-winning American entrepreneur and inventor in the area of biomimetic nanoscience and biopreservation in Regenerative Medicine. Being persistent in her life vision to enable “on-demand organs” from a very young age, she pursued her scientific endeavor in biomimetic Chemistry at SUNY Buffalo, earning her doctorate.
Inheriting the entrepreneurial spirit from her family, she successfully managed $8M in engineering projects while completing her Ph.D. Then she founded X-Therma in the San Francisco Bay Area in Oct 2014 to bring lab innovation to patients.
Dr. Wei is the inventor of X-Therma’s core technologies based on biomimetic hyper-effective ice prevention materials and devices, resulting in 17 issued global patents. She has served as principal investigator or co-PI of 12 national and international innovation research grants with accumulated value exceeding $14M USD from DoD, NSF, NIH, CIRM, EU etc. She has led the X-Therma research endeavors at The Molecular Foundry, Lawrence Berkeley National Laboratory 2015-2024. She serves as a healthcare advisor for the UC Regents working group on innovation transfer and entrepreneurship, is a scientific advisor for Life Extension Foundation, and was the Vice Chair of the Younger Chemists Committee of the American Chemical Society (ACS), and Cal ACS Executive Committee Member. She is currently a distinguished member of the RULEBREAKER Society, in Germany.
Moshe Levi, MD, is a professor in the Department of Biochemistry and Molecular & Cellular Biology at Georgetown University Medical Center.
Levi completed undergraduate training in chemical engineering at Northwestern University and received an MS in chemical engineering at Stanford University. He earned his MD from Albert Einstein College of Medicine and completed his internal medicine internship and residency at Cornell University and Memorial Sloan Kettering Hospital. He completed a nephrology clinical and research fellowship at the University of Colorado Health Sciences Center.
Funded by numerous NIH grants including three R01s in progress or concluding this year, Levi’s research involves renal and cardiovascular complications of obesity, diabetes and aging; regulation of mineral metabolism; and applying new label free techniques for imaging lipids, inflammation, oxidative stress, metabolism, and fibrosis. He has co-author 200 manuscripts and nearly 40 book chapters, and has mentored more than 20 MD or PhD research trainees.
Prior to joining Georgetown, from 2002 to 2017, Levi was professor of medicine, physiology and biophysics, and bioengineering at the University of Colorado Health Sciences Center, where from 2005 to 2011 he served as Vice Chair of Research for the Department of Medicine with over 400 faculty members. He also served on the executive committee of the NIH CCTSI Microscopy Technology Core Lab and the Clinical and Translational Imaging Research Center, and as a member of the Center for Fibrosis Research and Translation. Earlier in his career, Levi practiced medicine at the Department of Veterans Affairs Medical Center in Dallas where he was chief of the nephrology section, and at University of Texas Southwestern Medical Center from 1984 to 2002 where he was professor of internal medicine.
Levi has served on numerous study sections and associated grant review committees.
In 2013, he was appointed a member of the Board of Scientific Counselors for the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases and recently concluded his service as its chair.
Levi continues to serve as an NIH National Advisory Committee member for the Laboratory for Fluorescence Dynamics at the University of California Irvine, the O’Brien Center in Kidney Research at UT Southwestern Medical School and for the Beckman Laser Institute and UC Irvine.
Levi is a fellow of the American Heart Association, the American Society of Nephrology, and the American Physiological Society, and is a member of numerous professional associations where he has served in committees and leadership roles. Memberships include the American Physiological Society, the American Society of Nephrology, National Kidney Foundation, International Society of Nephrology, American Heart Association, American Diabetes Association, Juvenile Diabetes Research Foundation, the American Association for the Advancement of Science, Biophysical Society, American Society for Biochemistry and Molecular Biology, American Society for Cell Biology, and the American Association for the Study of Liver Disease.
He serves on the editorial boards of the Journal of Biological Chemistry, Diabetes, and American Journal of Physiology: Renal Physiology.
Levi is a married to a physician and is the father of two young adult children
Pamela A. Saunders, PhD (she, hers) is a professor in the departments of neurology and psychiatry. In 2024, she was named Co-Director of the Georgetown Center for Health Aging. Her research focuses on communicative coping behaviors, language, aging, doctor/patient communication, empathy, narrative and reflective writing, and standardized patient education. She has spent the last 30 years conducting research and teaching. Her research portfolio includes funding from the Alzheimer’s Association, the National Institute on Aging, the Hartford Foundation, and the U.S. Food and Drug Administration. She has served in several leadership roles, including director of the geriatrics clerkship and longitudinal thread in Aging & Geriatrics. She co-founded the geriatrics curriculum in 2003 at Georgetown’s School of Medicine with funding from the Hartford Foundation. Dr. Saunders is the founding director of the Aging & Health Program, which offers certificates and a master of science in Aging & Health (aging.georgetown.edu). Courses include reflective writing, Mind-Body Medicine skills to medical and graduate students, as well as courses in gerontology, reflective writing, research methods, and ageism. She lives in Falls Church, VA, with her husband, twin boys, and dog, Fancy.
Congressman Paul D. Tonko is a ninth-term member of the U.S. House of Representatives, representing New York’s 20th Congressional District in the Capital Region, including the cities of Albany, Amsterdam, Schenectady, Troy, Saratoga Springs.
He has dedicated his career in public service to bettering the lives of those in his district with meaningful legislation that creates good jobs, strengthens the middle class, and drives economic opportunity. Tonko is the Ranking Member of the Energy and Commerce Subcommittee on Environment, in addition to serving on the Energy and Commerce Subcommittee on Energy and Subcommittee on Oversight & Investigations.
This 119th Congress, he was selected to serve on the House Committee on the Budget. He also serves as Democratic Deputy Whip for Policy that works on the coordination and planning of the House Democratic Caucus’s policy.
Along with his committee duties, Tonko co-chairs the Sustainable Energy and Environment Coalition (SEEC), and the Addiction, Treatment, and Recovery (ATR) Caucus.
Prior to serving in Congress, he was the president and CEO of the New York State Energy Research and Development Authority. Before that, he served in the New York State Assembly for 25 years, serving for 15 years as Chairman of the Committee on Energy.
Tonko graduated from Clarkson University with a degree in mechanical and industrial engineering and is a former engineer for the New York State Public Service Commission.
Dr. Morgan Levine is a Vice President of Computation at Altos Labs and formerly a Principal Investigator at the San Diego Institute of Science.
Prior to joining Altos, Morgan was a ladder rank professor at Yale University School of Medicine. She is considered a leader in the biology of aging, most famous for generating cutting-edge methods for quantifying the system dysregulation that occurs over an organism’s lifetime. Her work relies on interdisciplinary approaches, integrating theories and techniques from computational and cellular biology to track trajectories aging cells and organisms take over time. Morgan’s vision is to develop multi-scale computational models that translate how dynamic molecular states of cells lead to manifestations of health and disease at the tissue, organ-system, or organismal level. She has received numerous awards for her work, including the Vincent Cristofalo Rising Star Award in Aging Research in 2021 and the Nathan Shock New Investigator Award in 2020.
Dr. O’Connor was awarded his master’s degree in neuroscience from Northwestern Medical in 1999 and his Ph.D. in Biochemistry from Baylor College of Medicine in 2005. His postdoctoral research includes work at UC Berkeley on muscle stem cells and aging. He is the former VP of Research at SENS Research Foundation where he oversaw a broad swath of research projects spanning many aspects of rejuvenation biotechnology from which he authored many papers and patents.
Matt Peloquin is the Senior Director of Research at Loyal which is developing therapeutics for lifespan extension in dogs. Matt’s research background is centered around understanding the biological drivers of metabolic disease and aging. Prior to Loyal, Matt was a discovery scientist at Pfizer developing drugs for metabolic and muscle wasting diseases in human health.
Louise Hecker, PhD is an Associate Professor at Baylor College of Medicine and the Founder and Chief Scientific Officer at Fibronox with over 15 years of experience in regenerative biology, fibrosis research, and age-related disease therapeutics. She is a world-leading expert on Nox4 and Nrf2, having made numerous seminal discoveries in understanding how oxidative stress contributes to tissue fibrosis and aging.
Her groundbreaking research has revolutionized the understanding of fibrotic diseases and recently expanded into psychedelic medicine, where her team discovered that psilocybin extends cellular lifespan by up to 57% and improves survival in aged mice. As an academic entrepreneur, she has founded five companies and secured approximately $15 million in research funding as Principal Investigator while holding around 20 patent applications. Read Psilocybin treatment extends cellular lifespan and improves survival of aged mice.
Louise currently serves as an Associate Professor in the Department of Medicine at Baylor College of Medicine since December 2024 and maintains her position as Founder and Chief Scientific Officer of Fibronox, a pharmaceutical startup she established in November 2017 to develop novel Nox4 inhibitors for treating fibrotic diseases.
Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan, Inc., Affiliate Professor of Oral Health Sciences at the University of Washington, and Co-Director of the Dog Aging Project. Dr. Kaeberlein’s research interests are focused on understanding biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life for people and companion animals. He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the Gerontological Society of America (GSA). Dr. Kaeberlein has published more than 250 scientific papers in the field of aging biology and has received several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer’s Association, the Vincent Cristofalo Rising Star in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology. Dr. Kaeberlein is the founding Director of the University of Washington Healthy Aging and Longevity Research Institute, former Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging and the Biological Mechanisms of Healthy Aging Training Program at the University of Washington, and former CEO and Chair of the American Aging Association.
Dr. Barnes’ principal professional interest is to develop therapies to protect valuable human lives against aging and age-related disease. He earned his BS in Biology from SUNY Oswego and his PhD in Neuroscience from Weill Cornell Medicine, after which he was a competitive intelligence consultant in the biotech space with focus on multiple types of chronic diseases including in ophthalmology. He founded Lento Bio at idea-stage in 2022 with the goal of developing novel treatments for chronic aging disorders of the lens, having in the 3 years since developed and patented Lento Bio’s current lead presbyopia asset.
Dr. Laura Niedernhofer is the Director of the Masonic Institute on the Biology of Aging and Metabolism (MIBAM) and Medical Discovery Team on the Biology of Aging. She is also a Professor in the Department of Biochemistry, Molecular Biology and Biophysics at UMN. Dr. Niedernhofer’s expertise is in DNA damage and repair, genome instability disorders, cellular senescence and aging. Her research program is centered on studying fundamental mechanisms of aging and developing therapeutics to target them. Her research program implements a murine model of a human progeroid syndrome caused by a defect in DNA repair. She contributed to the discovery of a new class of drugs called senolytics. Laura has served on study section for NCI, NIEHS and NIA. She has been awarded for research in aging, cancer and environmental health science.
Historically, the aging field was divided as to whether lifespan was dictated by genetics or environmental factors. We demonstrated that removing DNA repair defenses causes accelerated aging. This supports the conclusion that DNA damage can drive aging, if not repaired. Traditionally, biomedical research has focused on identifying molecular targets for treating a single disease. However, 75% of individuals over the age of 65 have 2 or more chronic degenerative diseases. My group has been at the forefront of seeking therapeutic interventions to treat aging itself and thereby prevent or attenuate multiple age-related diseases simultaneously. There is clearly an attrition of stem cell numbers and function with aging. But what was not clear is if this is a cause or consequence of aging. We demonstrated that the former is true, based on the finding that treating progeroid mice with muscle-derived stem cells from young mice was sufficient to slow down aging. This clearly shows that stem cell dysfunction contributes to aging and provides a scientific basis for treating age-related degenerative diseases with stem cell therapy.
There are over a thousand oncology studies in which the expression of ERCC1 repair protein is measured in tumors to determine if there is a correlation with response to therapy or patient outcomes. We discovered novel roles for ERCC1-XPF in the repair of DNA interstrand crosslinks and double-strand breaks, revealing important roles for the enzyme in coping with platinum-based and radiation therapy, respectively. In addition, we discovered that the antibody used to detect ERCC1 in tumoral tissue was non-specific. We discovered that the protein to which the antibody was cross-reacting was rate-limiting for cell growth and regulated by RAS.
Dr. Gladden the visionary founder of Gladden Longevity and Advanced Performance Center, initially practiced as an interventional cardiologist before pivoting his focus from late-stage interventions to preventing heart issues and unlocking ageless potential. Seamlessly blending science, wisdom, and innovation, he’s unraveling the secrets of Living Young for a Lifetime™, harmonizing Life Energy, Longevity, Health, and Human Performance. Beyond pioneering research, Dr. Gladden enjoys adventures in surfing, biking, hiking, snowboarding, and guitar playing. Amid these pursuits, he treasures moments with loved ones. Jeff’s dedication to inspiring vitality echoes through his work, driven by an unwavering commitment to guiding individuals toward embracing their potential and creating an enduring legacy in the world.
James C. Greenwood is a Senior Policy Advisor at the DLA Piper law firm, chairing its Life Science Health Policy and Regulatory group. He is the President Emeritus of the Biotechnology Industry Organization (BIO) in Washington, D.C., where he served as President and CEO from 2005-2020.
Mr. Greenwood represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee’s vast jurisdiction. Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992).
Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. Mr. Greenwood is married with three children and resides in Upper Makefield Township, Pennsylvania.
Joe Betts-LaCroix, CEO of Retro Biosciences, is dedicated to extending healthy human lifespan by ten years. A scientist-turned-entrepreneur, he began his career at Harvard, MIT, and Caltech, where he co-discovered key factors governing electron-tunneling rates in proteins, with his research published leading journals, accumulating over 1,500 citations.
Joe has co-founded three venture-backed startups. His first, OQO, created the world’s smallest Windows computer (Guinness World Record, 2006) and was later acquired by Google. His second, Vium, leveraged automation and AI to accelerate in vivo research and was acquired by Recursion Pharma. He also spent several years as a part-time partner at Y Combinator, mentoring and investing in biotech startups.
Now, as CEO of Retro Biosciences, he is bringing urgency and focus to the challenge of aging, leading a team exploring numerous novel approaches to longevity therapeutics. By accelerating discovery and translation, Retro aims to make meaningful gains in extending healthspan within our lifetime.
As CEO of Sinaptica, Ken is leading the team to advance the company’s personalized precision neuromodulation therapy for Alzheimer’s.
Prior to Sinaptica, Ken has 20+ years leading and growing new business ventures on both the ‘Buy Side’ and the ‘Build Side.’
He started his career in management consulting at Charles River Associates, then jumped to industry at CSL, then Baxter BioScience (now Takeda), and Boston Scientific, with leadership roles in marketing, strategy, and corporate development. At Boston Scientific’s nearly $1B Neuromodulation division, he was the global commercial lead for the highly successful Cosman RF ablation business he helped acquire.
He also built the division’s Strategy function, providing leadership in areas including strategic planning, BD assessment, R&D portfolio management, digital strategy, and investments in next-gen platforms & new indications. In 2019 he joined EBT Medical, a venture-backed, clinical-stage startup developing a disruptive neuromodulation device for overactive bladder, where he oversaw all commercial aspects.
Francisco LePort is co-founder and CEO of Gordian Biotechnology. Gordian Biotechnology has developed in vivo perturb seq technology that simultaneously measures the safety and efficacy of thousands of arbitrary genetic perturbations, directly in individual living animal models of any given age-related disease. Having raised $60M to date, Gordian is developing first-in-class therapeutics for obesity, heart failure, kidney disease, and osteoarthritis. Prior to Gordian, Francisco graduated with a BS in Physics from UC Irvine at the age of 17, and a Ph.D in Physics from Stanford University. He has over 15 years of experience applying AI to various industries as a founder, investor, board member, and employee of numerous Bay Area companies.
Frederick Beddingfield, MD
Dr. Beddingfield is a physician-scientist and biotech entrepreneur. He is currently CEO and Board Director of Rubedo Life Sciences. He also serves as Chairman of the Board of Sagesse Bio and as a director of Cytrellis Biosystems.
Previously he was an Executive Partner at Apollo Health Ventures, a longevity and age-related disease fund. He served as CEO and director of Kira Pharmaceuticals developing biologics for immunology, inflammation, and rare diseases from 2020 to 2023. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Previously he served as Chief Medical Officer of Kythera Biopharmaceuticals, acquired by Allergan in 2015. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac.
Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, and a Board Trustee of Advancing Innovation in Dermatology.
Dr. Hanadie Yousef is a scientist, entrepreneur, seasoned executive, and global thought leader in AI-driven regenerative medicine and longevity. With over two decades of experience in biomedical research, she is the Co-Founder of Juvena Therapeutics, where she served as CEO, CFO, and Board Chair from 2017 to 2025. Since the company’s incorporation, she pioneered its evolution from a platform-driven concept into a venture-backed, clinical-stage biotechnology leader. Under her leadership, Juvena secured over $105M in venture capital, non-dilutive grants, and partnerships, and developed a proprietary pipeline of tissue-restorative biologics for muscle and metabolic diseases.
Driven by a vision to decode the mechanisms of age-related tissue degeneration, Dr. Yousef leveraged Juvena’s AI-enabled JuvNET platform to map secreted proteins and build a proprietary library of pro-regenerative stem cell-secreted proteins and novel therapeutic candidates. Her leadership led to the successful completion of Phase 1 first-in-human safety studies for the company’s lead asset, JUV-161, targeting Myotonic Dystrophy Type 1 and atrophy-related muscle wasting.
Expanding the boundaries of metabolic health, she advanced a robust preclinical pipeline, including JUV-112, a groundbreaking obesity asset that uniquely enhances lipid metabolism to induce weight loss via an energy-promoting, non-appetite-suppressing mechanism. Validating this platform-first approach, Dr. Yousef secured a prestigious discovery partnership with Eli Lilly to develop novel medicines aimed at enhancing muscle health, body composition, and quality of life for patients with metabolic complications.
Dr. Yousef’s high-impact research has led to multiple issued and pending patents and has been supported by competitive fellowships and grants from the NIH, National Science Foundation, SPARK, and the California Institute for Regenerative Medicine (CIRM).
A recognized authority in the industry, Dr. Yousef was named to the 2025 Mayfield | Divot Industry Leader AI List and designated a World Economic Forum 2024 Technology Pioneer. Her extensive accolades include FierceBiotech’s “Fiercest Women in Life Sciences,” Business Insider’s “30 Leaders Under 40,” Endpoints’ “20(+2) Under 40,” the San Francisco Business Times “Women Who Lead in Life Sciences,” and the Biocom Catalyst Award.
Dr. Yousef is a regularly invited speaker at marquee biotech, AI, and healthcare innovation events. She earned her B.S. summa cum laude from Carnegie Mellon University, her PhD from UC Berkeley as an NSF Fellow, and completed a 5-year postdoctoral fellowship at Stanford School of Medicine as an NIH fellow and SPARK scholar. Her lifelong dedication to biomedical research and entrepreneurship began early, with research positions at Regeneron starting at age 15 and a neuroscience internship at Genentech.
Dr. Jean Hebert joined ARPA-H in August 2024 from the Albert Einstein College of Medicine where he served as a professor of genetics and neuroscience. Hebert is the founder of BE Therapeutics, a company focused on reversing age-related damage to brain tissue. His laboratory research focuses on stem cell transplantation, plasticity, neurodegeneration, and cortical health. In addition to his academic publications, Hebert is also the author of Replacing Aging, a book on regenerative medicine and the types of cellular damage accumulated in aging tissue.
Since childhood, Hebert has been interested in understanding how our bodies work and how to repair them. He has a doctorate in genetics from the University of California San Francisco and completed postdoctoral research at Stanford University studying the development of neurons that make up the neocortex.
Dylan V. Livingston is the founder and President of the Alliance for Longevity Initiatives (A4LI), the first 501(c)(4) organization in the U.S. devoted exclusively to advancing longevity science through public policy. He launched A4LI in 2022 to combat age-related diseases—including cancer, cardiovascular disease, and Alzheimer’s—by connecting scientific research with legislative action.
Under Livingston’s leadership, A4LI helped establish the bipartisan Longevity Science Caucus and supported state-level Right-to-Try expansion measures SB422 and SB535. He also founded the H-SPAN Summit in Washington, D.C., and led the organization’s first Longevity Science Congressional Briefing in 2024. In 2025, A4LI facilitated more than 70 meetings between advocates and members of Congress, and the 2026 summit will be held in partnership with Georgetown University Medical Center.
Livingston was recognized on Forbes 30 Under 30 for his work in building a national organization focused on longevity policy. Before founding A4LI, he gained experience on political campaigns, including serving as a field organizer for President Joe Biden’s 2020 campaign in Pennsylvania.
Mr. Schulak , Founder and Chairman of EdenRoc Sciences, is an architect, philanthropist, and life sciences investor.
He has served on numerous charitable, academic, and business boards, including the Sanford Burnham Prebys Medical Discovery Institute, the Advisory Board of the New York University Center for Urban Science and currently on the Boards of The University of Michigan Health System Advisory Group (Hospital, Research Center and Medical School), the Harvard Medical School Dean’s Discovery Council, Novim and the Dean’s Council for the University of California Baskin School of Engineering. Mr. Schulak graduated from the Rhode Island School of Design with degrees in both Fine Arts and Architecture.
Eric Morgen Eric is co-founder and Chief Operating Officer at BioAge. He has extensive experience in drug target and biomarker discovery using high-dimensional datasets from human cohorts, with >20 published papers spanning these areas in aging and diagnostic medicine.
Eric was previously an assistant professor at the University of Toronto. He completed residency, clinical fellowship, and a research fellowship in computational biology and molecular epidemiology at Mount Sinai Hospital and the University Health Network in Toronto, where he was also a Canadian Institutes of Health Research (CIHR) research fellow.
Eric received his MD, MPH, and bachelors in artificial intelligence from the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR. He is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, and holds a specialty designation in pathology.
Felipe Sierra, Ph.D. is CEO of Geroscience Consulting LLC. He is best known for his contributions to the development of the field of geroscience, a concept he developed while serving as Director of the Division of Aging Biology at the National Institute on Aging (NIA), part of the National Institutes of Health (NIH) in the USA.
Trained as a biochemist in Chile, he obtained a PhD in Biochemistry and Molecular Biology from the University of Florida in 1983 and has since worked in Academia, Industry and Government, in a career that spans multiple geographic areas including South America, USA, Europe (Switzerland and France) and most recently, the Middle East.
Dr. Sierra served as Director of the Division of Aging Biology, NIA/NIH from April 2006 to March 2020, where he developed the concept of Geroscience and created the trans-NIH Geroscience Interest Group (GSIG). After his tenure at NIA/NIH he worked as Director of Geroscience for the Inspire program in Toulouse, France, and most recently, as Chief Scientific Officer at Hevolution Foundation, a non-profit organization headquartered in Riyadh, Saudi Arabia. He retired from that position in March 2025 to start a private consulting venue, Geroscience Consulting LLC.
Dr. Christin Glorioso is a neuroscientist, physician, and serial entrepreneur. She is co-founder and CEO of NeuroAge Therapeutics and Founder and Executive Director of the non-profit, Longevity Global. Previously she was Head of AI of the Stanford Spinout, TeachAids. She has published more than 30 peer reviewed publications and been awarded grants by AFAR, the Glenn Foundation for Medical Research, and the National Institute on Aging. Dr. Glorioso holds an MD and PhD in Neuroscience from the University of Pittsburgh and Carnegie Mellon University’s Medical Scientist Training Program and completed her postdoctoral training at MIT.
Dr. Doug Lucas is a double board–certified orthopedic surgeon and longevity physician dedicated to changing how we understand aging, hormones, and bone health. After years in traditional orthopedic practice, he stepped away from a system that waited for bones to break before taking action and shifted his focus toward prevention, optimization, and healthspan. His work centers on a simple but disruptive idea: bone health is not a geriatric diagnosis—it is a powerful biomarker of longevity, resilience, and overall health.
Dr. Doug is the founder of The OsteoCollective, an international online community where thousands of women and men have successfully reversed osteoporosis and improved bone health with the right education, guidance, and support. He is also Head of Longevity at LifeMD, where he leads both the women’s and men’s health verticals, helping shape modern, proactive care models that integrate hormones, lifestyle, and long-term health optimization across midlife and beyond.
As the host of The Dr. Doug Show: Bones, Hormones & Healthspan and Health 3.0, and the author of two Amazon best-selling books, Dr. Doug is widely recognized for translating complex science into clear, actionable guidance. A sought-after speaker and media guest, he addresses topics ranging from osteoporosis prevention and reversal to hormone optimization, sexual health, metabolic resilience, and strength training for longevity.
Whether on stage, behind the microphone, or on camera, Dr. Doug’s mission is to educate the world that osteoporosis is often preventable, frequently reversible, and best understood not as inevitable decline—but as an opportunity to intervene early, build strength, and age with confidence, vitality, and purpose.
Cheryl Sew Hoy founded Tiny Health in 2020 after her first child struggled with eczema, sleep troubles, and food sensitivities. Her experience led her to research the gut microbiome and develop tests focusing on a baby’s first 1,000 days, a crucial period in microbiome development. Cheryl is a serial entrepreneur with extensive expertise in building consumer brands. She holds multiple Engineering degrees from Cornell University.
Christopher Bradley, MSc is the CEO and Cofounder of Matter Bio, a pioneering longevity biotechnology company focused on extending human healthspan through advanced genetic interventions, and an Adjunct Professor in the Department of Technology Management and Innovation at NYU Tandon School of Engineering. He is also the CEO and Founder of Loki Therapeutics, an immuno-oncology company developing next-generation cancer therapeutics.
Chris is a serial entrepreneur with a background in both biology and technology, with over a decade of executive experience founding, funding, and operating complex and innovative healthcare and biotechnology businesses. His current mission is to increase healthy human longevity by addressing two related problems: treating advanced cancer when it already exists and preserving DNA information integrity to prevent disease from emerging.
Dr. Tornatore is the Regional Chief of Neurology for MedStar Health and Chairman and Neurologist-in-Chief in the Department of Neurology at MedStar Georgetown University Hospital. He is also the Executive Director of the Multiple Sclerosis Patient Centered Specialty Practice MedStar Georgetown and Professor and Chairman in the Department of Neurology at Georgetown University Medical Center. Dr. Tornatore received his undergraduate degree in neurobiology from Cornell University and then attended Georgetown University School of Medicine where he received his medical degree. Following a Neurology Residency at Georgetown University Hospital, he was a post-doctoral fellow at the National Institute of Neurologic Disorders and Stroke at the National Institutes of Health. Dr. Tornatore has published extensively in the areas of neuroimmunology, neurovirology and Multiple Sclerosis and is currently involved in over 15 clinical trials for the treatment of Multiple Sclerosis. He has won multiple awards in the areas of medical student teaching, patient care and scholarly research.
Dr. Bill Rebeck is a Professor in the Department of Neuroscience at Georgetown University. He grew up in Cincinnati, OH, and attended Cornell University. After graduating, he worked for three years as a chemist at an agricultural products company and then earned a PhD in Toxicology at Harvard University in 1990. He spent one year on a Fulbright fellowship in Heidelberg, Germany, pursuing research on Alzheimer’s disease in the lab of Konrad Beyreuther. He then began research at Massachusetts General Hospital with Brad Hyman. He moved his lab to Georgetown University in 2003. For over 25 years, Dr. Rebeck, has been interested in genetic risk factors for Alzheimer’s disease, specifically variants of the APOE gene. His lab uses cell culture and mouse models to examine the effects of APOE isoforms on normal brain function prior to the accumulation of Alzheimer’s lesions. He has been very involved in graduate education, serving as assistant director of the MS in Integrative Neuroscience, director of the PhD program in Neuroscience for eight years, and Dean of the Graduate School of Arts and Sciences for 18 months. In 2017, Dr. Rebeck received the Georgetown Presidential Distinguished Scholar-Teacher award.
Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the NUS Medicine Healthy Longevity Translational Research Programme, and (3) the Asian Centre for Reproductive Longevity and Equality. Collectively, NUS aging research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.
From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell. Finally, Dr. Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.
Dr. Andrew Brack joined ARPA-H in April 2024 from the University of California San Francisco’s Department of Orthopaedic Surgery. For 16 years, his lab studied the cellular and molecular mechanisms that regulate skeletal muscle repair during aging. He was the co-founder of Arrive Bio, a longevity company that uses machine learning to identify drugs to treat age-related diseases.
Brack received a Ph.D. in molecular biology and biophysics from King’s College London and completed two postdoctoral fellowships, one at King’s College London and the second at Stanford University. Throughout his career Brack has led multidisciplinary teams with the goal of restoring healthy function during aging.
Dr. Alicia Jackson was appointed by President Trump as Director of the Advanced Research Projects Agency for Health (ARPA-H) and sworn in on October 20, 2025. Dr. Jackson reports directly to U.S. Department of Health and Human Services (HHS) Secretary.
Dr. Jackson joins ARPA-H from Evernow, a company she founded and led as CEO, focused on transforming women’s health and longevity during menopause. Previously, she served as a Program Manager and, subsequently, Deputy Director of the Defense Advanced Research Projects Agency’s Biological Technologies Office, guiding an investment portfolio across biodefense, novel medicine development, and biomanufacturing to protect the nation while advancing groundbreaking scientific capabilities. She has served as a Senate policy advisor, as well as co-founder, Board Member, and advisor of several biotech and health startups, including OOVA, ImmuneBridge, and Drawbridge Health.
Dr. Jackson holds a Ph.D. in materials science from the Massachusetts Institute of Technology.
Introducing Alina Su, founder and CEO of Generation Lab, the fastest-growing AI longevity company. Previously from Harvard Medical School, she co-founded Generation Lab with Dr. Irina Conboy — “the mother of longevity” who invented blood exchange from UC Berkeley Conboy Lab. Backed by tier 1 VCs like Accel and Samsung, Generation Lab created SystemAge, the world’s most accurate organ biological age test, with a personalized longevity plan. And now they are developing an injection shot that makes you young replacing blood exchange.
Already trusted by over 500 leading clinics worldwide and Hollywood A list celebrities from Kim Kardashian to Zac Efron, Naval Ravikant NBA NFL players — Generation Lab is creating the Ageless generation.
